TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20887365

Group type: EXPERIMENTAL
Intervention: Rufinamide (3,200 mg/day)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 19762663

Group type: EXPERIMENTAL
Intervention: Active household water filtration devices
Number of subjects: 988

Group type: COMPARATOR
Intervention: Sham household water filtration devices
Number of subjects: 988
Study: 17556686

Group type: EXPERIMENTAL
Intervention: Fructose test meal
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glucose test meal
Number of subjects: 14
Study: 15329830

Group type: COMPARATOR
Intervention: Doxylamine-pyridoxine combination (5-12 tablets/day)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Doxylamine-pyridoxine combination (1-4 tablets/day)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: No NVP
Number of subjects: 376
Study: 11432893

Group type: EXPERIMENTAL
Intervention: Topotecan 0.5 mg/m²/d and carboplatin AUC of 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topotecan 0.5 mg/m²/d and carboplatin AUC of 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topotecan 0.75 mg/m²/d and carboplatin AUC of 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topotecan 1.0 mg/m²/d and carboplatin AUC of 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topotecan 1 mg/m²/d and carboplatin AUC of 5
Number of subjects: 0
Study: 9058634

Group type: EXPERIMENTAL
Intervention: lansoprazole 30mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: pantoprazole 40mg
Number of subjects: 12
Study: 8345497

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (atenolol, nifedipine, captopril)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3453186

Group type: EXPERIMENTAL
Intervention: Intervention program focusing on nutrition, physical fitness, and cigarette smoking prevention
Number of subjects: 1822

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1822
Study: 30879163

Group type: EXPERIMENTAL
Intervention: Blastocystis sp. positive cases
Number of subjects: 340

Group type: COMPARATOR
Intervention: Blastocystis sp. negative controls
Number of subjects: 340
Study: 30514378

Group type: EXPERIMENTAL
Intervention: OPEN ARCH intervention (comprehensive, multidimensional geriatric assessment with care coordination)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: OPEN ARCH intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 27091810

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus aflibercept (4 mg/kg)
Number of subjects: 236

Group type: COMPARATOR
Intervention: mFOLFOX6 alone
Number of subjects: 236
Study: 24439981

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 3319
Study: 22108774

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg once daily (first dose 400 mg) for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Itraconazole 100 mg twice daily (first dose 200 mg) for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo twice daily for 5 days
Number of subjects: 12
Study: 20186679

Group type: EXPERIMENTAL
Intervention: Dacron graft
Number of subjects: 85

Group type: COMPARATOR
Intervention: ePTFE graft
Number of subjects: 85
Study: 17514541

Group type: EXPERIMENTAL
Intervention: Phonological awareness group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Language stimulation group
Number of subjects: 42
Study: 15516364

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (15 g down to 2.5 g daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 22
Study: 14533141

Group type: EXPERIMENTAL
Intervention: Milnacipran plus pindolol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Milnacipran plus placebo
Number of subjects: 80
Study: 11206017

Group type: EXPERIMENTAL
Intervention: Open-label dalteparin, administered before percutaneous coronary intervention within 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninvasive approach
Number of subjects: 0
Study: 8789431

Group type: COMPARATOR
Intervention: Isotretinoin alone (Roaccutan, Roche) 1 mg/kgr orally daily for 3 months or until remission achieved
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (Roferon‐A, Roche) 3 million units subcutaneously three times for 8 weeks plus isotretinoin 1 mg/Kg orally for 3 months or until remission achieved
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a plus isotretinoin
Number of subjects: 57
Study: 1435930

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 10 days
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 387
Study: 6723011

Group type: EXPERIMENTAL
Intervention: Protocol A (burst overdrive pacing, single, double, and triple extrastimuli at various sites)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Protocol B (burst overdrive pacing, single and double extrastimuli followed by triple extrastimuli at various sites)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Protocol A (triple extrastimuli at the first stimulation site)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Protocol B (triple extrastimuli)
Number of subjects: 101
Study: 3013104

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 18
Study: 31992300

Group type: EXPERIMENTAL
Intervention: 0.5 g whey protein hydrolysate [WPH]/ kg lean body mass
Number of subjects: 9

Group type: COMPARATOR
Intervention: Flavored water [PLA]
Number of subjects: 9
Study: 31051056

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) group performing six sessions of sprint interval training (SIT) over two weeks in a hyperbaric chamber (1.4 ATA, FiO2=1.0)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ambient group performing six sessions of sprint interval training (SIT) over two weeks under ambient pressure conditions (0.85 ATA, FiO2=0.21)
Number of subjects: 58
Study: 28916322

Group type: EXPERIMENTAL
Intervention: Intraductal stent
Number of subjects: 64

Group type: COMPARATOR
Intervention: No stent (control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Postoperative bile leak
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Multiplicity of bile ducts
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Biliary stricture
Number of subjects: 64
Study: 26519549

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccine
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard subcutaneous (SC) vaccine
Number of subjects: 900
Study: 23467600

Group type: EXPERIMENTAL
Intervention: Cepheid GeneXpert CT/NG (Xpert) assay for Chlamydia trachomatis
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Cepheid GeneXpert CT/NG (Xpert) assay for Neisseria gonorrhoeae
Number of subjects: 3109

Group type: EXPERIMENTAL
Intervention: Cepheid GeneXpert CT/NG (Xpert) assay for Neisseria gonorrhoeae in males
Number of subjects: 3109
Study: 21998318

Group type: EXPERIMENTAL
Intervention: Hypertension group
Number of subjects: 415476

Group type: COMPARATOR
Intervention: Nonhypertension group (control)
Number of subjects: 415476
Study: 18433677

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Nerve stimulation (n = 80)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 160
Study: 16531174

Group type: EXPERIMENTAL
Intervention: Reality female condom (FC1)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Synthetic latex prototype (FC2)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Both FC1 and FC2
Number of subjects: 276
Study: 12633915

Group type: EXPERIMENTAL
Intervention: Cocaine 12.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaine 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaine 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11113721

Group type: EXPERIMENTAL
Intervention: Crataegus Special Extract WS 1442 (450 mg, standardized to 84.3 mg of oligomeric procyanidines)
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 2300
Study: 9361129

Group type: EXPERIMENTAL
Intervention: Topical administration of Polypodium leucotomos (PL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral administration of Polypodium leucotomos (PL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (untreated or treated with oral psoralens)
Number of subjects: 21
Study: 1543431

Group type: EXPERIMENTAL
Intervention: Hand-rim propulsion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lever propulsion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Seat position changes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Trunk motion
Number of subjects: 15
Study: 3885736

Group type: EXPERIMENTAL
Intervention: Preterm Labor Prevention Clinic
Number of subjects: 132

Group type: COMPARATOR
Intervention: High-risk controls
Number of subjects: 132
Study: 29482627

Group type: EXPERIMENTAL
Intervention: Broad autoantibody profile (7-8 isotypes)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Broad autoantibody profile
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Broad baseline autoantibody profile
Number of subjects: 399
Study: 26407909

Group type: EXPERIMENTAL
Intervention: 500 mg kg‐1 per day topical CHE
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 1000 mg kg‐1 per day topical CHE
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 24838809

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation group (GPR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 34
Study: 22774774

Group type: EXPERIMENTAL
Intervention: Combination therapy (dutasteride + tamsulosin)
Number of subjects: 4574
Study: 20103694

Group type: EXPERIMENTAL
Intervention: Milnacipran 300 mg bid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg single dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fridericia formula (QTcF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Piecewise QTcNi correction method
Number of subjects: 100
Study: 18670715

Group type: EXPERIMENTAL
Intervention: Structured exercise intervention (three 50' group aerobics sessions per week for six months)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Structured exercise intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (ad libitum diet, no exercise)
Number of subjects: 78
Study: 15818465

Group type: EXPERIMENTAL
Intervention: 0.10 microM RTX
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.05 microM RTX
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 12728594

Group type: EXPERIMENTAL
Intervention: Walking exercise (12-week training programme)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual habitual physical activity (control group)
Number of subjects: 16
Study: 10430348

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 2.0 atm with inhalation of 100% oxygen for 60 min, at 3 hours and 24 hours after hepatectomy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (Group C) treated to maintain normal hemodynamic values
Number of subjects: 12
Study: 7539237

Group type: EXPERIMENTAL
Intervention: Liver resection combined with pre‐ and post‐operative locoregional chemotherapy‐immunotherapy (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Liver resection only (Group A)
Number of subjects: 40
Study: 2354101

Group type: EXPERIMENTAL
Intervention: Infraclavicular cannulation of the right subclavian vein with head turned towards the side
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Infraclavicular cannulation of the right subclavian vein with head turned away from the side
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Infraclavicular cannulation of the left subclavian vein with head turned towards the side
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Infraclavicular cannulation of the left subclavian vein with head turned away from the side
Number of subjects: 200
Study: 495533

Group type: EXPERIMENTAL
Intervention: High cholesterol diet (two egg yolks a day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Linoleic acid-rich diet (control)
Number of subjects: 41
Study: 29368862

Group type: EXPERIMENTAL
Intervention: UVA1 phototherapy (45 J/cm2, 22 sessions, 3 or 5 times per week)
Number of subjects: 12
Study: 31330044

Group type: EXPERIMENTAL
Intervention: Soil heterogeneity (three soil types assigned to patches)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Homogeneous plots (mixed soils)
Number of subjects: 34
Study: 29738389

Group type: EXPERIMENTAL
Intervention: Endolymphatic sac decompression with steroid injection (n=18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Endolymphatic sac decompression without steroid injection (n=17)
Number of subjects: 35
Study: 27089870

Group type: EXPERIMENTAL
Intervention: Internet-based educational intervention consisting of four educational sessions over a 4-week period.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual sex education provided by the school (comparison group).
Number of subjects: 0
Study: 24604110

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 40
Study: 22643131

Group type: EXPERIMENTAL
Intervention: SNP rs245178
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: SNP rs698172
Number of subjects: 115
Study: 19701243

Group type: EXPERIMENTAL
Intervention: Idiotypic vaccination
Number of subjects: 0
Study: 17592006

Group type: EXPERIMENTAL
Intervention: Pharmacies with policies and procedures for compounding and providing compounding training for staff
Number of subjects: 117

Group type: COMPARATOR
Intervention: Pharmacies without compounding policies and procedures and without staff training
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Training methods used by pharmacies that provided training
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Variability in formulations used to compound caffeine
Number of subjects: 117
Study: 15341667

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (0.3 g/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isonitrogenous placebo supplementation
Number of subjects: 0
Study: 12297845

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (3 million units 3 times a week) plus ribavirin (1,000 mg/day) for 48 weeks
Number of subjects: 113

Group type: COMPARATOR
Intervention: Interferon alfa‐2b alone for 48 weeks
Number of subjects: 113
Study: 9503102

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol combined with a diuretic
Number of subjects: 0
Study: 8301791

Group type: EXPERIMENTAL
Intervention: 22‐mg nicotine patch
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 240
Study: 3382069

Group type: EXPERIMENTAL
Intervention: Immediate whole‐bowel irrigation with a polyethylene glycol solution
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 50 g oral activated charcoal followed by whole‐bowel irrigation
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal alone
Number of subjects: 3

Group type: COMPARATOR
Intervention: 24‐hour urine collection only
Number of subjects: 3
Study: 29551981

Group type: EXPERIMENTAL
Intervention: Resisted Sprint Training (RST)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Traditional Power Training (TPT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Passive Control Group
Number of subjects: 35
Study: 27219253

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 25948437

Group type: EXPERIMENTAL
Intervention: Grape seed extract 2% cream
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 23101282

Group type: EXPERIMENTAL
Intervention: Combination of propafenone and bisoprolol (group B, n = 82)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Propafenone alone (group A, n = 82)
Number of subjects: 164
Study: 20495925

Group type: EXPERIMENTAL
Intervention: Liquid taste solutions with different concentrations of each tastant (sweet 0.03, 0.1, 0.4, 2 g/mL sucrose solution; sour 0.01, 0.05, 0.1, 0.15 mL citric acid; salty 0.025, 0.075, 0.15, 0.36 mL sodium chloride solution; bitter 0.0002, 0.0005, 0.001, 0.01 mL quinine hydrochloride)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Liquid taste solutions
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Total score at the 10th percentile
Number of subjects: 944
Study: 18946064

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg or 24 mg per day) for 36 months
Number of subjects: 334

Group type: COMPARATOR
Intervention: Interferon beta‐1a (44 microg three times per week) for 36 months
Number of subjects: 334
Study: 15913458

Group type: EXPERIMENTAL
Intervention: Lumbar fusion surgery
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-surgical care
Number of subjects: 300
Study: 12043954

Group type: EXPERIMENTAL
Intervention: Fed (high-fat breakfast)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fasted
Number of subjects: 12
Study: 8986493

Group type: EXPERIMENTAL
Intervention: Diazepam (0.5 mg/kg loading dose followed by 1 mg/kg infusion over 24 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (equivalent volume)
Number of subjects: 0
Study: 2404838

Group type: EXPERIMENTAL
Intervention: RA 233 (N = 251)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo (N = 246)
Number of subjects: 497
Study: 6769159

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 261
Study: 31717728

Group type: EXPERIMENTAL
Intervention: Four 30‐min daily outdoor unstructured play periods for 8 weeks
Number of subjects: 185

Group type: COMPARATOR
Intervention: Two 60‐min outdoor sessions (control)
Number of subjects: 185
Study: 28698349

Group type: EXPERIMENTAL
Intervention: Resistance training and protein supplementation (RTPS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Protein supplementation (PS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 26338726

Group type: EXPERIMENTAL
Intervention: Metronidazole group (lansoprazole 30 mg, amoxicillin 1 g, bismuth potassium citrate 220 mg, metronidazole 400 mg)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Clarithromycin group (lansoprazole 30 mg, amoxicillin 1 g, bismuth potassium citrate 220 mg, clarithromycin 500 mg)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Metronidazole group
Number of subjects: 215

Group type: COMPARATOR
Intervention: Clarithromycin group
Number of subjects: 215
Study: 23022646

Group type: EXPERIMENTAL
Intervention: Early decompressive craniectomy for diffuse TBI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 0
Study: 21722580

Group type: EXPERIMENTAL
Intervention: Contrast baths
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical stimulation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heating pads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight bearing on the foot
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General activities of daily living
Number of subjects: 0
Study: 19066196

Group type: EXPERIMENTAL
Intervention: Self-collected specimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinician-collected specimens
Number of subjects: 0
Study: 17329522

Group type: EXPERIMENTAL
Intervention: Bladder flap (n=21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No bladder flap (n=19)
Number of subjects: 40
Study: 15162983

Group type: EXPERIMENTAL
Intervention: F+20 protocol
Number of subjects: 22

Group type: COMPARATOR
Intervention: F+0 protocol
Number of subjects: 22

Group type: COMPARATOR
Intervention: F-15 protocol
Number of subjects: 22
Study: 11414375

Group type: EXPERIMENTAL
Intervention: Asking participants questions about their uncertainty
Number of subjects: 3

Group type: COMPARATOR
Intervention: Not asking participants questions about their uncertainty
Number of subjects: 3
Study: 10067003

Group type: EXPERIMENTAL
Intervention: Selective attention tasks for individuals with OCD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective attention tasks for individuals with panic disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective attention tasks for control participants
Number of subjects: 0
Study: 7625378

Group type: EXPERIMENTAL
Intervention: 30 Gy perioperative brachytherapy for ILR (Group A)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 60-70 Gy exclusive split-course brachytherapy for ILR (Group B)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 38
Study: 2172535

Group type: EXPERIMENTAL
Intervention: Perilesional injections of alpha-interferon (twice-weekly)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 14
Study: 206208

Group type: EXPERIMENTAL
Intervention: Vincristine for a period of 2 years from diagnosis
Number of subjects: 114

Group type: COMPARATOR
Intervention: Actinomycin D for a period of 2 years from diagnosis
Number of subjects: 114
Study: 30957213

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) with monitoring reminders, elevated potassium warnings, and hyperkalaemia alerts.
Number of subjects: 34253

Group type: COMPARATOR
Intervention: Control group (no CDS intervention).
Number of subjects: 34253

Group type: EXPERIMENTAL
Intervention: Intervention group (with CDS intervention).
Number of subjects: 34253
Study: 28781360

Group type: EXPERIMENTAL
Intervention: Reduction Osteotomy (RO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Extensive Release (ER)
Number of subjects: 24
Study: 24711542

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30